Small molecule FPR/NOX2 agonists

Development of proprietary unique nM potent agonist of FPR/NOX2

for treatment of autoimmunity, inflammation and infections


The FET Open Horizon 2020 project under the acronym NeutroCure, in which Redoxis together with Pronoxis is one of the partners, has been granted by the EU commission.

The project is focused on the development of smart amplifiers of reactive oxygen species to aberrant polymorphonuclear neutrophils for the treatment of inflammatory and autoimmune diseases, cancer and myeloablation and is a collaboration with academic groups in Germany, the United Kingdom, Ukraine, Spain and France. In the NeutroCure project, we will be able to combine our knowledge and interest in redox regulation of the immune system with our preclinical in vivo model platform.

Redoxis main role in the NeutroCure project will be preclinical efficacy and mode of action characterization. The project has a total budget of approximately 3 000 000 € over 5 years and Redoxis activities have been granted 400 000 €